| Literature DB >> 26567141 |
Lavakumar Karyampudi1, Purushottam Lamichhane2, James Krempski3, Kimberly R Kalli4, Marshall D Behrens3, Doris M Vargas3, Lynn C Hartmann4, Jo Marie T Janco5, Haidong Dong3, Karen E Hedin3, Allan B Dietz6, Ellen L Goode7, Keith L Knutson8.
Abstract
The PD-1:PD-L1 immune signaling axis mediates suppression of T-cell-dependent tumor immunity. PD-1 expression was recently found to be upregulated on tumor-infiltrating murine (CD11c(+)CD11b(+)CD8(-)CD209a(+)) and human (CD1c(+)CD19(-)) myeloid dendritic cells (TIDC), an innate immune cell type also implicated in immune escape. However, there is little knowledge concerning how PD-1 regulates innate immune cells. In this study, we examined the role of PD-1 in TIDCs derived from mice bearing ovarian tumors. Similar to lymphocytes, TIDC expression of PD-1 was associated with expression of the adapter protein SHP-2, which signals to NF-κB; however, in contrast to its role in lymphocytes, we found that expression of PD-1 in TIDC tonically paralyzed NF-κB activation. Further mechanistic investigations showed that PD-1 blocked NF-κB-dependent cytokine release in a SHP-2-dependent manner. Conversely, inhibition of NF-κB-mediated antigen presentation by PD-1 occurred independently of SHP-2. Collectively, our findings revealed that PD-1 acts in a distinct manner in innate immune cells compared with adaptive immune cells, prompting further investigations of the signaling pathways controlled by this central mediator of immune escape in cancer. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26567141 PMCID: PMC4715980 DOI: 10.1158/0008-5472.CAN-15-0748
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701